PAVmed

PAVmed Liabilities

The The Liabilities of PAVmed (PAVM) as of Oct 28, 2026 is 16.51 M USD. In the previous year, The Liabilities was 37.69 M USD — a change of -56.19% (lower).

Liabilities

16.51 MUSD

YoY

-56.19%

Last updated:

In 2025, PAVmed's total liabilities amounted to 16.51 M USD, a -56.19% difference from the 37.69 M USD total liabilities in the previous year.

The PAVmed Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
10.97 M USD
Jan 1, 2019
11.88 M USD
Jan 1, 2020
20.25 M USD
Jan 1, 2021
7.56 M USD
Jan 1, 2022
43.05 M USD
Jan 1, 2023
57.14 M USD
Jan 1, 2024
37.69 M USD
Jan 1, 2025
16.51 M USD
The PAVmed Liabilities history
YEARLiabilitiesYoY
16.51 MUSD-56.19%
37.69 MUSD-34.03%
57.14 MUSD+32.73%
43.05 MUSD+469.54%
7.56 MUSD-62.68%
20.25 MUSD+70.48%
11.88 MUSD+8.26%
10.97 MUSD+144.49%
4.49 MUSD+277.31%
1.19 MUSD+105.02%
580,172.00USD+1,127.90%
47,249.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PAVmed Stock analysis

What does PAVmed do? PAVmed, Inc. generates revenue through the development and commercialization of medical devices including PortIO, a vascular access device without central venous system access or indwelling intravascular components, and CarpX, a percutaneous device for carpal tunnel syndrome treatment. The company also offers NextCath, a self-anchoring catheter eliminating the need for suturing or traditional anchoring methods, and DisappEAR, antibiotic-eluting resorbable ear tubes utilizing aqueous silk technology. Additional products include NextFlo, a disposable infusion system with variable flow resistors, and Caldus, a disposable tissue ablation device. Medical device companies and healthcare providers purchase these products for patient treatment and surgical procedures. The firm's product portfolio targets specific medical needs such as vascular access, orthopedic procedures, and ear treatments. PortIO serves patients requiring long-term vascular access without traditional central line risks. CarpX addresses carpal tunnel syndrome through minimally invasive procedures. DisappEAR provides a solution for ear tube insertion using resorbable technology, reducing the need for follow-up surgeries. NextCath streamlines catheter placement in medical settings. PAVmed's commercial strategy focuses on medical device companies and healthcare providers seeking innovative solutions for vascular access, orthopedic interventions, and ear care. The company's products are designed to improve patient outcomes while reducing procedural complexity and costs. By leveraging proprietary technologies like aqueous silk for DisappEAR, PAVmed differentiates its offerings in the medical device market. PAVmed is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing PAVmed's Liabilities

PAVmed's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating PAVmed's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing PAVmed's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

PAVmed's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in PAVmed’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about PAVmed stock

The Liabilities of PAVmed is 16.51 M USD in 2025.

The Liabilities of PAVmed changed from 37.69 M USD to 16.51 M USD, representing a -56.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities PAVmed since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's PAVmed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — PAVmed

All Key Metrics — PAVmed